Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Assets (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Assets for 5 consecutive years, with $28.5 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 2.59% year-over-year to $28.5 million; the TTM value through Mar 2026 reached $122.6 million, up 62.78%, while the annual FY2025 figure was $30.2 million, 65.95% up from the prior year.
  • Non-Current Assets hit $28.5 million in Q1 2026 for Phathom Pharmaceuticals, down from $30.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $32.5 million in Q3 2025 and bottomed at $3.3 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $15.8 million, with a median of $14.6 million recorded in 2024.
  • Year-over-year, Non-Current Assets surged 288.41% in 2024 and then dropped 2.59% in 2026.
  • Phathom Pharmaceuticals' Non-Current Assets stood at $4.3 million in 2022, then surged by 281.81% to $16.4 million in 2023, then rose by 10.81% to $18.2 million in 2024, then soared by 65.95% to $30.2 million in 2025, then fell by 5.39% to $28.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $28.5 million, $30.2 million, and $32.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.